Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes

Prim Care Diabetes. 2022 Jun;16(3):471-473. doi: 10.1016/j.pcd.2022.03.012. Epub 2022 Apr 5.


Given the CV benefit noted in the CVOTs, GLP-1RAs and SGLT-2is are given preference in T2DM guidelines. While guidelines do not report potential gender difference, those differences exist. On restricting the CVOTs results to women with increased CV risk or established ASCVD, GLP-1RAs significantly reduced MACE while SGLT-2is resulted in a non-significant reduction.

Keywords: CVOT; GLP-1 receptor agonist; SGLT-2 inhibitors; Type 2 diabetes; Women.

MeSH terms

  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Diabetes Mellitus, Type 2* / diagnosis
  • Diabetes Mellitus, Type 2* / drug therapy
  • Female
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects


  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors